27th Nov 2013 09:47
LONDON (Alliance News) - GW Pharmaceuticals PLC Wednesday said that its prescription treatment for Multiple Sclerosis spasticity, Sativex, has been approved by Swiss regulators.
In a statement, the cannaboid pharmaceuticals company said the timing of a launch in Switzerland will depend on the completion of pricing and reimbursement procedures.
The Swiss regulator gave marketing approval for treatment of moderate to severe spasticity in Multiple Sclerosis patients who have not responded adequately to other anti-spasticity medications.
Switzerland is the 23rd country that Sativex is approved in.
GW Pharma shares were up 3.6% at 180.33 pence Wednesday morning.
By Steve McGrath; [email protected]; @SteveMcGrath1
Copyright © 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
GWP.L